Paris (France), 25 January 2011 – The association of the five leading French pharmaceutical groups, known as the G5, has announced that, due to exceptional circumstances affecting his company, Dr. Jacques Servier has informed them of his decision to resign as Chairman of the G5 in order to devote his time to defending his company’s interests.
In this context, the leading French pharmaceutical groups would like to reiterate their commitment:
§ to serving patients to the best of their abilities through innovation, support to best clinical guidelines and constant monitoring of their medicines.,
§ to enhancing, when they are legitimate, their relations with healthcare professionals and the Authorities so as to contribute to health safety and improve patients trust.
To achieve this, the G5 supports the proposals to increase the transparency of the industry. In particular, it fully endorses the proposal to publish the links between experts and the companies, as well as the amount of the sums paid to the former.
Marc de Garidel (Chairman & CEO of Ipsen) has been elected Chairman of the G5, while Olivier Bohuon (Directeur General of Laboratoires Pierre Fabre) is appointed spokesman and Christian Béchon (CEO of LFB) takes responsibility for relations with biotechnology companies.
These decisions will enable the G5 to pursue its activities focused on leveraging the excellence of French biomedical research and the attractiveness of the country, and on reinforcing the innovation capabilities and international reputation of France.
About the G5
The G5 is an association of French pharmaceutical companies that acts as a think tank and regularly issues proposals to highlight the excellence of French biomedical research and the attractiveness of the country, and focuses on reinforcing the innovation capabilities and international reputation of France.
Ipsen, Pierre Fabre, sanofi-aventis, Servier and LFB are all companies whose decision-making centres are based in France, and their activities cover all aspects of the pharmaceutical industry. They are all internationally competitive and make research efforts a high priority. At a global scale, the G5 is a major stakeholder, achieving sales worth €34 billion (6.5% of worldwide sales by the industry) and investing €5.84 billion in R&D (9% of the total).
These companies, which have chosen France as the platform for their international development, employ nearly 44,000 people, achieve a surplus of €7 billion for the French trade balance, have an R&D budget of €2.44 billion and account for 40% of jobs and about half of investments and research staff in the sector.
Marie-Madeleine de Montera
Mobile: 00 33 (0)6 03 45 87 83 – Telephone: 00 33 (0)1 47 05 92 56
e-mail: email@example.comRevenir à la liste des articles